News
One of the main factors determining therapeutic antibodies’ half-life is the interaction between the antibody’s Fc region and ...
Annexon has completed enrollment in its phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular ...
The drug is indicated for the treatment rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic ...
A new study done by scientists in Switzerland and Sweden investigated the use of automated systems to develop multispecific ...
DelveInsight's CD40/CD40L Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...
16d
Pharmaceutical Technology on MSNLupin and Zentiva in licence and supply deal for Certolizumab PegolZentiva Group has entered a licence and supply agreement with Lupin for the commercialisation of latter’s biosimilar Certolizumab Pegol.
Measles is one of 100 viruses that the team at VUMC is systematically making antibodies for by using single-cell sequencing — ...
Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for commercialization of Lupin's biosimilar, TNF alpha inhibitor medicine, across ...
17d
ET Now on MSN$ 50 million! Lupin signs licensing deal with European pharma company for THIS - DetailsPharma major Lupin has signed a USD 50 million agreement with a European pharmaceutical company. Lupin has entered into a license and supply agreement to commercialize its biosimilar Certolizumab ...
Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...
Trusval Technology reported consolidated revenue of NT$670 million (approx. US$22.9 million) in June 2025, a 39% monthly and 136% annual increase. Benefitting from strong customer demand, their ...
"All three types of myasthenia gravis, based on antibody status, can have similar symptoms," said Henry Kaminski, MD, of George Washington University in Washington, D.C. "Most patients have droopy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results